A MED13 gene knockout sgRNA, mutant cell line and its application in inhibiting pseudorabies virus replication

By constructing the MED13 gene mutant cell line in cells, using the CRISPR/Cas9 system to knock out the MED13 gene significantly inhibit the replication of pseudorabies virus, solving the problem of PRV irrepressible, improving the cell's resistance, and developing antiviral drugs It provides new targets, reduces damage to cells and animals, and has important significance in disease control in the pig industry.

CN118497205BActive Publication Date: 2024-11-08AGRO BIOLOGICAL GENE RES CENT GUANGDONG ACADEMY OF AGRI SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410947569.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-08
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Pseudorabies virus (PRV) is difficult to be effectively inhibited by the host through various immune evasion mechanisms, especially in the transcriptional regulation process involving the MED13 gene, the existing technology lacks effective inhibitory means.

Method used

The sgRNA and CRISPR/Cas9 gene editing system for MED13 gene knockout were designed to construct the MED13 gene mutant cell line, which significantly inhibits the replication of PRV in IPEC-J2 cells and improves the resistance of cells to PRV infection.

Benefits of technology

Through the construction of the MED13 gene mutant, the replication amount of PRV in cells is significantly reduced, the cell's resistance to PRV infection is improved, and new antiviral targets are provided, reducing the toxicity to cells and animals is of great significance to the pig farming industry. Disease control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118497205B_ABST
    Figure CN118497205B_ABST
Patent Text Reader

Abstract

The invention discloses a MED13 gene knockout sgRNA, a mutant cell line and an application thereof in inhibiting pseudorabies virus replication, and belongs to the field of genetic engineering technology. The invention designs sgRNA for MED13 gene sequence and inserts it into PX459 vector to construct PX459-sgRNA-MED13 recombinant plasmid; the recombinant plasmid is introduced into IPEC-J2 cells to obtain a monoclonal cell line with MED13 gene knockout; and the monoclonal cell line with MED13 gene knockout is verified by fluorescence quantitative PCR and Western Blot experiments to significantly inhibit the replication of pseudorabies virus, which is of great significance for the prevention and treatment of pseudorabies virus infection diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of genetic engineering, and in particular to a MED13 gene knockout sgRNA, a mutant cell line and an application thereof in inhibiting the replication of pseudorabies virus. Background Art

[0002] MED13 (Mediator complex subunit 13, MED13) is a component of the Mediator complex and is a coactivator that exists in the cell nucleus and is involved in the transcriptional regulation of almost all genes that depend on RNA polymerase II. Mediator plays a bridging role, transmitting information from gene-specific regulatory proteins to the basic RNA polymerase II transcription machinery. MED13 plays a key role in the cell cycle, development, and growth. As previous studies have found that mammalian Med13 is a substrate of Cdk8, the Cdk8 kinase module (CKM) is a separable Mediator subunit. In the cell nucleus, the Cdk8 module consists of cyclin C, Cdk8, and two other proteins, Med12 and Med13. The Cdk8 module is one of the components of the cyclin C-Cdk8 kinase, and the function of the cyclin C-Cdk8 kinase is mainly to inhibit gene transcription. Recent studies have found that Med13 is an anchor protein that can retain cyclin C in the nucleus if it is not destroyed. The release of cyclin C from the nucleus requires Slt2 phosphorylation and Med13 destruction, which may be mediated by Cdk8 phosphorylation.

[0003] Pseudorabies virus (PRV) has evolved multiple immune evasion mechanisms against host antiviral immune responses. The results show that PRV UL13 antagonizes IFN signaling through a novel mechanism, targeting STING to continuously evade the host's antiviral response. The mediator protein is an evolutionarily conserved multiprotein complex that acts as a basic connector in the transcription machinery of eukaryotes to mediate interactions between different proteins. It interacts with RNA polymerase II and participates in the process of gene expression. Related studies have shown that MED19 is also involved in lipid metabolism and the pathogenesis of coronavirus disease 2019 (COVID-19). Purified transcription components phosphorylate the RNAPII carboxyl-terminal domain (CTD) to initiate transcription, and viral transcription activators enhance this effect. The transcription activator viral protein 16 (VP16, α-TIF, and Vmw65) of herpes simplex virus (HSV) is particularly valuable in transcriptional assays. Virologists have found that VP16 and adenovirus E1A proteins are associated with a large complex with cyclin C / CDK8 kinase activity. Therefore, MED13 may be associated with the infection process of PRV, but there is no relevant report yet. Summary of the invention

[0004] The purpose of the present invention is to provide a MED13 gene knockout sgRNA, a mutant cell line and an application thereof in inhibiting the replication of pseudorabies virus to solve the problems existing in the above-mentioned prior art. The sgRNA designed by the present invention can knock out the MED13 gene and construct a MED13 gene mutant. Experiments have shown that the MED13 gene mutant can significantly inhibit the replication of PRV in IPEC-J2 cells and improve the resistance of cells to PRV infection.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides the use of sgRNA for targeted knockout of MED13 gene in any of the following items:

[0007] (1) Application in constructing MED13 gene mutants;

[0008] (2) Use in the preparation of drugs for inhibiting the replication of pseudorabies virus;

[0009] (3) Use in the preparation of drugs for inhibiting the replication of pseudorabies virus in IPEC-J2 cells;

[0010] The nucleotide sequence of the sgRNA is shown in SEQ ID NO.2, and the gene accession number of the MED13 gene on NCBI is 100628203.

[0011] The present invention also provides the use of a CRISPR / Cas9 gene editing system for targeted knockout of the MED13 gene in any of the following:

[0012] (1) Application in constructing MED13 gene mutants;

[0013] (2) Use in the preparation of drugs for inhibiting the replication of pseudorabies virus;

[0014] (3) Use in the preparation of drugs for inhibiting the replication of pseudorabies virus in IPEC-J2 cells;

[0015] Among them, the nucleotide sequence of the sgRNA of the CRISPR / Cas9 gene editing system is shown in SEQ ID NO.2, and the gene accession number of the MED13 gene on NCBI is 100628203.

[0016] The present invention also provides a method for producing a mutant cell line with a knockout of the MED13 gene, comprising: using the MED13 gene as an editing target gene, knocking out the MED13 gene in the cell using the CRISPR / Cas9 gene editing system, and constructing a mutant cell line with a knockout of the MED13 gene;

[0017] Among them, the nucleotide sequence of the sgRNA of the CRISPR / Cas9 gene editing system is shown in SEQ ID NO.2, and the gene accession number of the MED13 gene on NCBI is 100628203.

[0018] Preferably, the target sequence for knocking out the MED13 gene in the cell is as shown in SEQ ID NO.1.

[0019] Preferably, the cell is a mammalian cell.

[0020] Preferably, the mammalian cell is an IPEC-J2 cell.

[0021] The present invention also provides a mutant cell strain with MED13 gene knockout prepared by the method.

[0022] The present invention also provides the use of the mutant cell strain with MED13 gene knockout in screening targets for inhibiting pseudorabies virus.

[0023] The present invention discloses the following technical effects:

[0024] The present invention designs a sgRNA sequence that can target and knock out the MED13 gene, and constructs a mutant IPEC-J2 cell line with MED13 gene knockout based on CRISPR / Cas9 gene editing technology. The mutant IPEC-J2 cell line has no obvious difference from the control cells. The construction method provided by the present invention is simple to operate, short in cycle and low in cost.

[0025] The present invention finds through fluorescent quantitative PCR and Western Blot experiments that the MED13 gene mutant can significantly inhibit the replication of PRV in IPEC-J2 cells and improve the resistance of cells to PRV infection.

[0026] The MED13 gene provided by the present invention provides a new target for the subsequent development and application of antiviral drugs. As a target for anti-PRV, gene knockout or development of related drugs targeting the target can reduce damage to cells and toxicity to mammals such as pigs. The study of PRV is of great significance to disease control in the pig industry. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0028] Figure 1 This is the pSpCas9-2A-Puro(PX459)V2.0 vector map;

[0029] Figure 2 This is the sequencing map of the PX459 (MED13 -sgRNA) plasmid;

[0030] Figure 3 This is the peak diagram of CRISPR target site sequencing of MED13 wild-type IPEC-J2 cell line;

[0031] Figure 4 This is the peak diagram of CRISPR target site sequencing of MED13 mutant IPEC-J2 cell line (MED13-KO1);

[0032] Figure 5 This is the peak diagram of CRISPR target site sequencing of MED13 mutant IPEC-J2 cell line (MED13-KO2);

[0033] Figure 6 This is a sequence alignment diagram of the IPEC-J2 cell MED13 wild-type and mutant monoclonal cell lines (MED13-KO1, MED13-KO2); the three sequences from top to bottom correspond to the wild-type, MED13-KO1, and MED13-KO2, respectively;

[0034] Figure 7 The results of cell viability test of IPEC-J2 MED13 wild-type and mutant monoclonal cell lines MED13-KO1 and MED13-KO2;

[0035] Figure 8 The effects of MED13 wild-type IPEC-J2 cell line and mutant IPEC-J2 cell lines MED13-KO1 and MED13-KO2 on PRV replication;

[0036] Fig. 9 The effect of MED13 wild-type IPEC-J2 cell line and mutant IPEC-J2 cell lines (MED13-KO1 and MED13-KO2) on the expression of PRV-gE protein. DETAILED DESCRIPTION

[0037] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0038] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0039] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0040] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0041] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0042] Example 1

[0043] 1. Construction of knockout vector

[0044] 1.1 Design and synthesize sgRNA

[0045] According to the published MED13 gene sequence (NCBI Gene ID: 100628203), the open reading frame ORF region and exons were determined, and the target sequence was designed and determined according to the CRISPR vector design principles. The target sequence action site designed this time was located in the exon region of the MED13 gene (12689..12709). The target sequence obtained by removing the 3' end PAM sequence NGG was: 5'-AAGCAAAGTACGGCATTCGT -3' (SEQ ID NO.1), and the sgRNA sequence for targeted editing of the DNA sequence was: 5'-AAGCAAAGUACGGCAUUCGU -3' (SEQ ID NO.2). CACCG was added to the 5' end of the target sequence to form a forward Oligo DNA (MED13-Oligo-F), and CAAA was added to the 5' end of the DNA sequence corresponding to the reverse complement of the target sequence, and C was added to the 3' end to form a reverse Oligo DNA (MED13-Oligo-R).

[0046] Forward Oligo DNA (MED13-Oligo-F): 5'- CACCG AAGCAAAGTACGGCATTCGT-3' (SEQ ID NO. 3);

[0047] Reverse Oligo DNA (MED13-Oligo-R): 5'- AAAC ACGAATGCCGTACTTTGCTT C -3' (SEQ ID NO. 4).

[0048] 1.2 Construction of PX459 (MED13-sgRNA) plasmid

[0049] The forward oligo DNA and reverse oligo DNA (MED13-Oligo-F, R) were annealed to form dsDNA. The reaction procedure was: incubation at 37℃ for 25 min, annealing at 95℃ for 6 min, gradient down to 12℃, 5℃ / min. Reaction system (20 μL): forward oligo DNA (MED13-Oligo-F) 2μL (final concentration 10 μM), negative oligo DNA (MED13-Oligo-R) 2 μL (final concentration 10 μM), 10×T4 Ligation Buffer 2 μL, T4 PNK (10 U / μL) 1 μL (final concentration 5 U) and ddH2O 13 μL.

[0050] Take the dsDNA formed after annealing and anneal with the pSpCas9-2A-Puro(PX459)V2.0 vector (see Figure 1 ) ligation, the reaction program is: incubate at 37℃ for 10 min, 23℃ for 6 min, for a total of 25 cycles, the gradient is reduced to 12℃, 5℃ / min. Ligation system (20 μL): 2 μL of annealed dsDNA, 2 μL of 10×T4 Ligation Buffer, 50 ng of PX459 plasmid, 1 μL of Bbs I (5 U / μL), 1 μL of T4 ligase (400 U / μL), and ddH2O to make up the total volume to 20 μL.

[0051] 1.3 Transformation and screening and identification of PX459 (MED13-sgRNA) positive clones:

[0052] (1) Take out the DH5α competent cell suspension, dissolve it on ice, and dispense it into 50 μL per tube;

[0053] (2) Add 5 μL of plasmid DNA solution (the ligation product described above) to each tube of 50 μL DH5α competent cell suspension, pipette to mix well, and place on ice for 30 min.

[0054] (3) Heat shock in a 42°C water bath for 90 s; immediately cool on ice for 5 min;

[0055] (4) After cooling, add 500 μL of LB liquid culture medium to the tube, mix well, and culture at 37°C with shaking for 1 h.

[0056] (5) Prepare LB solid culture plates containing Amp, take 100 μL of the bacterial solution after 1 h of culture, drop it onto the culture plate and spread it evenly, and culture it in a 37°C incubator for 16 h.

[0057] (6) On the second day, pick a single colony and inoculate it into 1 mL of LB liquid medium containing Amp. Incubate the culture in a shaking incubator at 37°C and 200 rpm.

[0058] (7) Design primers, perform colony PCR on the selected single colonies, and send them to Beijing Qingke Biotechnology Co., Ltd. for sequencing using the U6 promoter. The sequencing map of the PX459 (MED13-sgRNA) plasmid is shown in Figure 2 .

[0059] 2. Construction of MED13 gene-deficient cell lines

[0060] First, primers were designed for the DNA region containing sgRNA, and then cells were plated into new six-well plates and the sgRNA was expressed using Lipo8000. TMTransfection reagent was used for transfection, and PX459 (MED13-sgRNA) was transferred into the cell nucleus, and culture was continued for 48 h. After 48 h, complete medium containing 4 μg / mL puromycin was used for continuous screening, and fresh complete medium containing puromycin was replaced every two days until most cells died. Subsequently, monoclonal dilution was performed using a 96-well plate, and the obtained monoclonal cells were transferred from the 96-well plate to a 12-well plate for further expansion and culture. The genomic DNA of different monoclonal cells was extracted, and high-fidelity PCR was performed. The PCR products were sent to Bioengineering for sequencing.

[0061] The PCR primers were MED13-F: 5'-GTTGATCAATCGGCACCCCT C -3' (SEQ ID NO. 5), MED13-R: 5'-AACTCAGTGAGGGGACATAGG -3' (SEQ ID NO. 6). The PCR products were sent to Beijing Qingke Biotechnology Co., Ltd. for sequence determination and sequence analysis.

[0062] See the CRISPR target site sequencing peak diagram of MED13 wild-type IPEC-J2 cell line for details. Figure 3 The peak diagram of CRISPR target site sequencing of MED13 mutant IPEC-J2 cell line (MED13-KO1) is shown in Figure 4 See the peak diagram of CRISPR target site sequencing of MED13 mutant IPEC-J2 cell line (MED13-KO2) for details. Figure 5 After comparison, it can be found that compared with the CRISPR target site sequence of the MED13 wild-type IPEC-J2 cell line (see Figure 6 ), a "T" base was inserted or a "C" base was missing in the target sequence of MED13, resulting in a frameshift mutation and producing a non-functional protein, thus achieving the purpose of knocking out the gene.

[0063] 3. Effects of MED13 wild-type IPEC-J2 cell lines and mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2) on PRV replication

[0064] 3.1 CCK-8 assay

[0065] 1×10 per well 4IPEC-J2 cell lines and MED13 mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2) were plated in 96-well plates, with 6 replicate wells for each treatment, and cultured for 24 h, 48 h, and 72 h. According to the CCK-8 kit, 10 μL of CCK-8 solution was added to the designated culture wells at different time points, incubated at 37°C for 2 h, and then the absorbance at 450 nm was detected by a microplate reader. The experiment was repeated 3 times.

[0066] like Figure 7 As shown, there was no significant difference in the absorbance value at OD 450 nm between the mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2) and the wild-type IPEC-J2 cell lines (P>0.05). The results showed that knocking out the relevant genes had no significant effect on the proliferation of the mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2).

[0067] 3.2 qPCR validation

[0068] After the MED13 wild-type IPEC-J2 cell line and mutant IPEC-J2 cell line (MED13-KO1, MED13-KO2) were cultured to stability, the cells were inoculated with 0.1 MOI of PRV virus. After 48 h of infection, the supernatant was collected by repeated freezing and thawing three times, and viral DNA was extracted using the Solebo Animal Cell / Tissue Genomic DNA Extraction Kit for SYBR Green qPCR. The primers are as follows:

[0069] Table 1 qPCR primers

[0070] name serial number Sequence (5'-3') PRV-F SEQ ID NO.7 AACATCCTCACCGACTTCAT PRV-R SEQ ID NO.8 GGCGTCAGGAATCGCATCAC β-actin-F SEQ ID NO.9 TCCACGAAACTACCTTCAACTC β-actin-R SEQ ID NO.10 GTGATCTCCTTCTGCATCCTG

[0071] like Figure 8 As shown, the results showed that 48 h after PRV infection of MED13 wild-type IPEC-J2 cell line and mutant IPEC-J2 cell line (MED13-KO1, MED13-KO2), the viral load of PRV in MED13 mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2) was significantly lower than that in MED13 wild-type IPEC-J2 cell line.

[0072] 3.3 Western Blot Verification

[0073] After collecting protein solution from 6-well plates of MED13 wild-type IPEC-J2 cell lines and mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2) infected with PRV for 48 h, 5× Loading Buffer was added and heated at 100℃ for 10 min to collect samples. The samples were subjected to polyacrylamide gel electrophoresis and transferred to PVDF membrane. The membranes were blocked with 5% skim milk powder solution for 1.5 h and washed with TBST. The membranes were incubated with 1:3000 diluted β-actin Monoclonal Antibody (5B7) and 1:500 diluted PRV-gE monoclonal antibody at 4℃ overnight and washed with TBST three times. The membranes were incubated with 1:3000 diluted HRP-goat anti-mouse IgG (H+L) on a shaker at 60 rpm for 1 h and washed with TBST three times. ELC chemiluminescent colorimetric solution was added and the membranes were imaged using a gel imaging system.

[0074] The imaging results are as follows Fig. 9 As shown, the results showed that after PRV infected the MED13 mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2), the MED13 gene in the mutant IPEC-J2 cell lines (MED13-KO1, MED13-KO2) had been knocked out, affecting the expression of gE protein, resulting in a significant inhibition of the gE protein expression level in PRV.

[0075] The above results show that the MED13 gene knockout IPEC-J2 cell line was successfully constructed by the method of the present invention and can effectively resist PRV infection. The present invention optimizes sgRNA to construct a target cell line MED13-KO1 and MED13-KO2, and knocks out the key gene MED13 of PRV in the cell, thereby improving the resistance of cells to PRV infection and reducing damage to cells or mammals such as pigs. The study of PRV is of great significance to disease control in the pig industry.

[0076] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Application of sgRNA targeting MED13 gene knockout in any of the following: (1) Application in constructing a mutant IPEC-J2 cell line with MED13 gene deletion; (2) Use in the preparation of drugs for inhibiting the replication of pseudorabies virus in IPEC-J2 cells; in, The nucleotide sequence of the sgRNA is shown in SEQ ID NO.2, and the gene accession number of the MED13 gene on NCBI is 100628203.

2. Application of CRISPR / Cas9 gene editing system for targeted knockout of MED13 gene in any of the following: (1) Application in constructing a mutant IPEC-J2 cell line with MED13 gene deletion; (2) Use in the preparation of drugs for inhibiting the replication of pseudorabies virus in IPEC-J2 cells; in, The nucleotide sequence of the sgRNA of the CRISPR / Cas9 gene editing system is shown in SEQ ID NO.2, and the gene accession number of the MED13 gene on NCBI is 100628203.

3. A method for producing a mutant cell line with MED13 gene knockout, characterized in that: include: Using the MED13 gene as the editing target gene, the CRISPR / Cas9 gene editing system was used to knock out the MED13 gene in IPEC-J2 cells, and a mutant cell line with MED13 gene knockout was constructed; Among them, the nucleotide sequence of the sgRNA of the CRISPR / Cas9 gene editing system is shown in SEQ ID NO.2, and the gene accession number of the MED13 gene on NCBI is 100628203.

4. The method according to claim 3, characterized in that The target sequence for knocking out the MED13 gene in cells is shown in SEQ ID NO.

1.

5. A mutant cell line with MED13 gene knockout obtained by the method according to any one of claims 3-4.